Literature DB >> 21879389

MicroRNA replacement therapy for cancer.

Jon C Henry1, Ana Clara P Azevedo-Pouly, Thomas D Schmittgen.   

Abstract

MicroRNA are small noncoding RNAs that translationally repress their target messenger RNAs. Many microRNAs are expressed at reduced levels in tumors. microRNAs with reduced expression in cancer often regulate oncogenes, resulting in enhanced tumor growth. One therapeutic option is to restore microRNA levels in the tumor to that of the non-diseased tissue. This is possible by delivering microRNA to the tumor in the form of an oligonucleotide mimic or by expressing the microRNA in the cancer using a gene vector. This article surveys the field of oligonucleotide mimics and gene vector approaches to restore microRNA levels in tumors and reviews the literature on experimental and pre-clinical studies that have used these approaches to treat cancer.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21879389     DOI: 10.1007/s11095-011-0548-9

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  119 in total

1.  New class of microRNA targets containing simultaneous 5'-UTR and 3'-UTR interaction sites.

Authors:  Inhan Lee; Subramanian S Ajay; Jong In Yook; Hyun Sil Kim; Su Hyung Hong; Nam Hee Kim; Saravana M Dhanasekaran; Arul M Chinnaiyan; Brian D Athey
Journal:  Genome Res       Date:  2009-03-31       Impact factor: 9.043

Review 2.  Transcriptional regulation and transformation by Myc proteins.

Authors:  Sovana Adhikary; Martin Eilers
Journal:  Nat Rev Mol Cell Biol       Date:  2005-08       Impact factor: 94.444

Review 3.  MicroRNAs and their therapeutic potential for human diseases: microRNAs, miR-143 and -145, function as anti-oncomirs and the application of chemically modified miR-143 as an anti-cancer drug.

Authors:  Yukio Kitade; Yukihiro Akao
Journal:  J Pharmacol Sci       Date:  2010-10-09       Impact factor: 3.337

4.  MicroRNA-101 is down-regulated in gastric cancer and involved in cell migration and invasion.

Authors:  Hui-Ju Wang; Hong-Jun Ruan; Xu-Jun He; Ying-Yu Ma; Xiao-Ting Jiang; Ying-Jie Xia; Zai-Yuan Ye; Hou-Quan Tao
Journal:  Eur J Cancer       Date:  2010-08       Impact factor: 9.162

5.  MicroRNA miR-199a* regulates the MET proto-oncogene and the downstream extracellular signal-regulated kinase 2 (ERK2).

Authors:  Seonhoe Kim; Ui Jin Lee; Mi Na Kim; Eun-Ju Lee; Ji Young Kim; Mi Young Lee; Sorim Choung; Young Joo Kim; Young-Chul Choi
Journal:  J Biol Chem       Date:  2008-05-02       Impact factor: 5.157

6.  The let-7 microRNA reduces tumor growth in mouse models of lung cancer.

Authors:  Aurora Esquela-Kerscher; Phong Trang; Jason F Wiggins; Lubna Patrawala; Angie Cheng; Lance Ford; Joanne B Weidhaas; David Brown; Andreas G Bader; Frank J Slack
Journal:  Cell Cycle       Date:  2008-03-03       Impact factor: 4.534

7.  Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers.

Authors:  George Adrian Calin; Cinzia Sevignani; Calin Dan Dumitru; Terry Hyslop; Evan Noch; Sai Yendamuri; Masayoshi Shimizu; Sashi Rattan; Florencia Bullrich; Massimo Negrini; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-18       Impact factor: 11.205

8.  The muscle-specific microRNA miR-206 blocks human rhabdomyosarcoma growth in xenotransplanted mice by promoting myogenic differentiation.

Authors:  Riccardo Taulli; Francesca Bersani; Valentina Foglizzo; Alessandra Linari; Elisa Vigna; Marc Ladanyi; Thomas Tuschl; Carola Ponzetto
Journal:  J Clin Invest       Date:  2009-07-20       Impact factor: 14.808

9.  Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma.

Authors:  Laura Gramantieri; Manuela Ferracin; Francesca Fornari; Angelo Veronese; Silvia Sabbioni; Chang-Gong Liu; George A Calin; Catia Giovannini; Eros Ferrazzi; Gian Luca Grazi; Carlo M Croce; Luigi Bolondi; Massimo Negrini
Journal:  Cancer Res       Date:  2007-07-01       Impact factor: 12.701

Review 10.  Novel RNA-based strategies for therapeutic gene silencing.

Authors:  Christopher R Sibley; Yiqi Seow; Matthew J A Wood
Journal:  Mol Ther       Date:  2010-01-19       Impact factor: 11.454

View more
  52 in total

Review 1.  In vivo delivery of miRNAs for cancer therapy: challenges and strategies.

Authors:  Yunching Chen; Dong-Yu Gao; Leaf Huang
Journal:  Adv Drug Deliv Rev       Date:  2014-05-22       Impact factor: 15.470

2.  Passenger strand loading in overexpression experiments using microRNA mimics.

Authors:  Rolf Søkilde; Inga Newie; Helena Persson; Åke Borg; Carlos Rovira
Journal:  RNA Biol       Date:  2015       Impact factor: 4.652

3.  Overcoming obstacles in microRNA delivery towards improved cancer therapy.

Authors:  Dikla Ben-Shushan; Ela Markovsky; Hadas Gibori; Galia Tiram; Anna Scomparin; Ronit Satchi-Fainaro
Journal:  Drug Deliv Transl Res       Date:  2014-02       Impact factor: 4.617

4.  Single-stranded microRNA mimics.

Authors:  Guillaume Chorn; Molly Klein-McDowell; Lihong Zhao; Matthew A Saunders; W Michael Flanagan; Aarron T Willingham; Lee P Lim
Journal:  RNA       Date:  2012-08-21       Impact factor: 4.942

Review 5.  The role of microRNAs in chronic respiratory disease: recent insights.

Authors:  Lindsay R Stolzenburg; Ann Harris
Journal:  Biol Chem       Date:  2018-02-23       Impact factor: 3.915

Review 6.  Functional role and therapeutic targeting of microRNAs in inflammatory bowel disease.

Authors:  Artin Soroosh; Marina Koutsioumpa; Charalabos Pothoulakis; Dimitrios Iliopoulos
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2017-11-16       Impact factor: 4.052

7.  Musashi1 Impacts Radio-Resistance in Glioblastoma by Controlling DNA-Protein Kinase Catalytic Subunit.

Authors:  Patricia Rosa de Araujo; Aparna Gorthi; Acarizia E da Silva; Sonal S Tonapi; Dat T Vo; Suzanne C Burns; Mei Qiao; Philip J Uren; Zhi-Min Yuan; Alexander J R Bishop; Luiz O F Penalva
Journal:  Am J Pathol       Date:  2016-07-25       Impact factor: 4.307

8.  Therapeutic Silencing of miR-214 Inhibits Tumor Progression in Multiple Mouse Models.

Authors:  Daniela Dettori; Francesca Orso; Elisa Penna; Désirée Baruffaldi; Serena Brundu; Federica Maione; Emilia Turco; Enrico Giraudo; Daniela Taverna
Journal:  Mol Ther       Date:  2018-08-01       Impact factor: 11.454

Review 9.  DNA methylation and microRNA dysregulation in cancer.

Authors:  Hiromu Suzuki; Reo Maruyama; Eiichiro Yamamoto; Masahiro Kai
Journal:  Mol Oncol       Date:  2012-08-10       Impact factor: 6.603

10.  Reversal of microRNA-150 silencing disadvantages crizotinib-resistant NPM-ALK(+) cell growth.

Authors:  Coralie Hoareau-Aveilla; Thibaud Valentin; Camille Daugrois; Cathy Quelen; Géraldine Mitou; Samuel Quentin; Jinsong Jia; Salvatore Spicuglia; Pierre Ferrier; Monica Ceccon; Sylvie Giuriato; Carlo Gambacorti-Passerini; Pierre Brousset; Laurence Lamant; Fabienne Meggetto
Journal:  J Clin Invest       Date:  2015-08-10       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.